H.R. 4055: Dialysis-Related Amyloidosis Treatment Act of 2025
This bill, titled the Dialysis-Related Amyloidosis Treatment Act of 2025, aims to amend the Social Security Act to enhance Medicare coverage for treatments related to dialysis-related amyloidosis, a complication that can arise in patients undergoing dialysis. The key components of the bill include:
Coverage for Treatments
The bill proposes to add coverage for treatments specifically designed to address dialysis-related amyloidosis under Medicare. This involves an amendment to Section 1861(s)(2) of the Social Security Act, which will include a new subparagraph (KK) that recognizes treatments for this condition.
Definition of Treatments
It stipulates that "treatments for dialysis-related amyloidosis" encompasses any FDA-approved items or services provided in dialysis facilities, whether they are freestanding or hospital-based. This also includes necessary supplies and services that support these treatments.
Payment Structure
The bill introduces a specific payment structure for these treatments. Currently, treatments related to renal dialysis are included in a bundled payment system. This bill allows dialysis-related amyloidosis treatments to be billed separately, ensuring that payment is made at 100 percent of the reasonable charges for the items and services provided, rather than being encompassed in the existing renal dialysis payment amounts.
Exclusions from Existing Services
The bill will amend Section 1881(b)(14)(B) of the Social Security Act to further clarify that treatments for dialysis-related amyloidosis are not categorized as part of renal dialysis services, thus providing a distinct classification and treatment pathway under Medicare.
Effective Date
The amendments outlined in this bill will become effective once the bill is enacted into law.
Relevant Companies
- None found
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
2 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Jun. 20, 2025 | Introduced in House |
| Jun. 20, 2025 | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
Potentially Relevant Congressional Stock Trades
No relevant congressional stock trades found.